HOME
CLIENT SERVICES
Technical Strategy
Due Diligence
Project Management
Expert Witness
ABOUT
DAVID DODDS
     Biography
     Resume
     Patents
     Publications
     Presentations


  View LinkedIn Profile    Download PDF File

DAVID R. DODDS, Ph.D.

4686 Druids Glen MOBILE:   315 884 3703
Manlius, NY 13104 USA SKYPE:      daviddodds4
www.techdiligence.net ddodds@techdiligence.net

SUMMARY

Thirty years at the interface of organic chemistry and biotechnology, and ten years of successful interdisciplinary consultancy serving small/start-up pharma, chemical and industrial biotech companies.  

Provides CTO-level management and patent liaison for operations, and technical due diligence for investment. Extensive experience interacting with academics, staff scientists, patent counsel and business-development in start-ups. 

Directed multi-disciplinary process development groups in major pharmaceutical corporations. Built new, practical technology base within both small company and large corporate environments. Delivered profitable IP, process scale-up, and novel automation. Extensive project management experience covering process chemistry, molecular biology, biotransformations & biocatalysis, plus fermentation of natural products and recombinant enzymes and biobased chemicals. Developed and scaled processes for the biological production of commodity chemicals from biomass, including cost-analyses. Extensive experience under GMP; provided CMC sections of IND & NDA filings. Excellent communication skills; frequently invited to explain technical issues to patent, licensing, regulatory, and business groups, and to serve on due-diligence teams. Expert witness experience. Service as North American Editor of international peer-reviewed journal and as Chairs of international symposia in the field of biocatalysis. United States and Canadian citizenships.

 
APPOINTMENTS
 
2002- Principal, Dodds & Associates LLC
2014- Executive officer, ASTM Committee E62 Industrial Biotechnology
2012- Co-founder, Sriya DXI LLC
2012- PureVison Technology, Inc. Scientific Advisory Board
2005- Sr. Advisor, Rondaxe Pharma LLC
2002- ZuChem Scientific Advisory Board & CSO, zuSyn, Inc. (zuChem subsidiary, 2007-9)
2012-15 CTO, Pronghorn Renewables LLC
2009-12 Kent BioEnergy Scientific Advisory Board
2003-06 Sr. Advisor, Michigan Biotechnology Institute (MBI)
2002-08 Codexis Industrial Advisory Board
1999-01 Director, Fermentation & Biocatalysis Development, Bristol-Myers Squibb
1998-02 North American Editor, Journal of Molecular Catalysis B: Enzymatic
1991-99 Manager, Biotransformations Group Schering-Plough Research Institute
1986-91 Senior Protein Biochemist, Sepracor Inc.

PRESENTATIONS, PATENTS and PUBLICATIONS
(see links, and Google Scholar)

EDUCATION

1984-86 PDF Molecular Biology, University of Colorado, Boulder, Prof. Marvin H. Caruthers
1979-84 Ph.D., Organic Synthesis, University of Toronto, Prof. J. Bryan Jones
1977-79 M.Sc., Biological Chemistry, University of Toronto
1973-77 B.Sc., Biochemistry, Trinity College, University of Toronto

PROFESSIONAL EXPERIENCE
 
INDEPENDENT CONSULTING; DODDS & ASSOCIATES LLC
www.techdiligence.net
2002-      
Founded Dodds & Associates to provide strategic technical planning and project management to the pharmaceutical, biotech, and chemical industries. Work with small and start-up companies needing interdisciplinary experience at a CTO-level to establish technical strategy, manage IP, and execute project management. Extensive industrial and academic network. Executed contracts with over two dozen clients since 2002. Client references available.
Completed and current projects include:
Service on technical Advisory Boards; technical presentations to Corporate Boards and investors
Intellectual property review and strategy, technical assessment and due-diligence
Project Management:
-process review, development, and scale-up for both pharma and non-pharma projects including industrial biotechnology
-contractor selection, site visits and reporting, technology transfer
-drafting CMC sections for IND & NDA, batch record drafting and review for GMP production
-develop and run biological/fermentation processes for production of non-fuel commodity chemicals from biomass
Interim technical executive for small entities:
-CTO-level management; intellectual property review and competitor technology review, patent liaison
-interim CSO for client; responsible for lab build-out, technology base, contract work & staffing
-identification of technical opportunities for investment, due-diligence, preparation of white-papers for investment fund, presentations to regional development committees
Expert witness; experience in depositions and cross-examination
BRISTOL-MYERS SQUIBB CO. , SYRACUSE, NEW YORK
DIRECTOR, FERMENTATION & BIOCATALYSIS DEVELOPMENT
ASSOCIATE DIRECTOR, ENZYME DEVELOPMENT
1999 - 2001
2000 - 2001
1999 - 2000

Invited to BMS to lead a new group of 50 scientists organized into chemical process development, molecular biology, fermentation development, and GMP analytical functions. Managed $4 million in annual operating and capital budgets. Achieved cost-savings by applying biocatalysis in chemical syntheses and evaluated these with outsourcing group. Developed chiral chemical processes, plus fermentations for natural products, enzyme production, and biocatalysis.
Solved production problems with enzymatic process experienced by an external supplier. Recovered over 3 tons of in-process material critical to launch supply to meet specifications.
Developed process to chiral intermediate for HIV therapeutic via biological reduction, allowing significant cost-savings over vendor pricing of tonne quantities.
Developed natural product fermentation process that gave a three-fold increase in production within 12 months. Re-wrote and updated all documentation necessary for GMP compliance.
Conceived and managed chemical gene synthesis and expression project to replace bovine enzyme and eliminate TSE/BSE regulatory issues in an existing commercial process.
Directed submission of six chemical and fermentation process patent applications in 18 months.
With neither a budget nor formally assigned project, managed preparation of an existing facility - designed for other purposes - for first half of TAXOL